Literature DB >> 2564113

Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis.

G W Taylor1, I Taylor, P Black, N H Maltby, N Turner, R W Fuller, C T Dollery.   

Abstract

The leukotrienes LTC4, D4, and E4 are potent bronchoconstrictor agents and are thought to have an important role in asthma. Urinary LTE4, a stable urinary end-product of LTC4 and LTD4, was measured, by means of high-performance liquid chromatography and radioimmunoassay. LTE4 excretion followed a log-normal distribution in twenty-nine healthy controls, with a geometric mean of 23.8 (95% confidence interval 19.9-28.2) ng/mmol creatinine. Urine was collected from eight atopic subjects for 3 h after antigen inhalation and a control urine collection was made a week later at the same time of day. Urinary LTE4 was significantly higher after antigen challenge than in the control sample (153.7 [87.1-271.3] vs 23.5 [13.7-69.5] ng/mmol creatinine; p less than 0.01). Urinary LTE4 was also measured in twenty patients with severe acute asthma and nine patients with seasonal allergic rhinitis. Mean urinary LTE4 was higher in the asthmatic patients (78.3 [46.5-131.8] ng/mmol creatinine) than in normal subjects (p less than 0.01), although there was substantial overlap into the normal range. The urinary LTE4 values of the rhinitis patients were within the normal range whether or not they had symptoms. LTC4 and LTD4 were also found in bronchoalveolar lavage fluid from one of the three atopic subjects challenged with antigen before lavage, and in a single patient who underwent lavage after admission with severe acute asthma. These studies provide evidence that leukotrienes are released in vivo in man after antigen challenge and in acute asthma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564113     DOI: 10.1016/s0140-6736(89)91611-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  52 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis.

Authors:  R A Simon
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 3.  Antileukotrienes and laboratory models of asthma.

Authors:  S C Lazarus
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

4.  Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma.

Authors:  Y Nakamura; M Hoshino; J J Sim; K Ishii; K Hosaka; T Sakamoto
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

5.  Pharmacological profile of leukotrienes E4, N-acetyl E4 and of four of their novel omega- and beta-oxidative metabolites in airways of guinea-pig and man in vitro.

Authors:  M N Samhoun; D M Conroy; P J Piper
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

6.  Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers.

Authors:  T C O'Shaughnessy; P Georgiou; K Howland; M Dennis; C H Compton; N C Barnes
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

Review 7.  Leukotriene activity modulation in asthma.

Authors:  S L Spector
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

8.  Effects of corticosteroids in acute severe asthma.

Authors:  N C Barnes
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

Review 9.  The organization and consequences of eicosanoid signaling.

Authors:  Roy J Soberman; Peter Christmas
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

10.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on antigen-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; D A Burroughs; M Yeadon; C P Page
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.